What did Needham change in the HIMS analyst rating on March 9, 2026?

Needham upgraded Hims & Hers (HIMS) to **Buy** on March 9, 2026. The note appeared at **11:24 AM** and the market reacted up **1.42%**. No public price target was released in the StreetInsider summary.

How did other firms affect the HIMS analyst rating mix the same day?

On March 9, 2026 BTIG reiterated **Neutral** at **10:15 AM** and BofA kept **Underperform** at **8:46 AM**. Combined, the notes produced mixed signals rather than consensus for HIMS.

Does the new HIMS analyst rating include price targets I can trade on?

None of the March 9, 2026 summaries we reviewed published a new price target. The Needham upgrade was substantive on stance but not target-driven, so investors should check full analyst reports before trading.

How should I use the HIMS analyst rating updates in my portfolio decisions?

Treat the HIMS analyst rating updates as one input. Use them alongside financials, partnership terms, and Meyka AI’s **B+** grade. Rebalance only after confirming fundamentals and risk tolerance.

Analyst Ratings

Needham upgrades Hims & Hers (HIMS) to Buy on March 9, 2026

ByHuzaifa Zahoor March 10, 2026March 10, 2026

On March 9, 2026 Needham upgraded Hims & Hers Health, Inc. (HIMS) to Buy. The move shifted the HIMS analyst rating mix for investors early that day. BTIG maintained Neutral at 10:15 AM, and BofA Securities reiterated Underperform at 8:46 AM on March 9, 2026. Needham’s upgrade coincided with a modest market reaction of 1.42% (up $0.31). Meyka AI rates HIMS with a grade of B+ and we track how these analyst calls affect positioning for a company with a market cap of $4,866,569,565.